The Global Initiative for Chronic Obstructive Lung Disease (GOLD) published its first report
for the diagnosis and management of chronic obstructive pulmonary disease (COPD) in …

Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and
cumulative gene–environment interactions over a lifetime. The evolving understanding of …

Inhaled corticosteroids (ICS) are the most commonly used anti-inflammatory drugs for the
treatment of COPD. COPD has been previously described as a “corticosteroid-resistant” …

Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, progressive
inflammatory airway disease associated with a significant impact on patients' lives, including …

Background Chronic obstructive pulmonary disease (COPD) is associated with airway
inflammation and bacterial dysbiosis. The relationship between the airway microbiome and …

Pharmacological treatment for chronic obstructive pulmonary disease (COPD) aims to
alleviate symptoms and reduce the future risk of events such as exacerbations, disease …

To the Editor, Type 2 (T2) inflammation in asthma encompasses the presence of
eosinophilic inflammation and/or selected cytokines including interleukin (IL)-13. Some …

Aim The impact of blood eosinophil counts on the development of chronic obstructive lung
disease (COPD) is unknown. We investigated whether a higher blood eosinophil count was …

Abstract Background Interleukin (IL)‐33 is an upstream regulator of type 2 (T2) eosinophilic
inflammation and has been proposed as a key driver of some asthma phenotypes. Objective …

Background Accelerated lung function decline is characteristic of COPD. However, the
association between blood eosinophil counts and lung function decline, accounting for …